Article information
Full text is only aviable in PDF
References
[1]
MC Fiore, WC Bailey, SJ Cohen, SF Dorfman, MG Goldstein, ER Gritz, et al.
Treating tobacco use and dependence. Clinical practice guideline, US Department of Health and Human Services. Public Health Service, (2000),
[2]
P Tønnesen, L Carrozzi, KO Fagerström, C Gratziou, CA Jimenez-Ruiz, S Nardini, et al.
Task Force Recommendations: Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy.
Eur Respir J, 29 (2007), pp. 390-427
[3]
RL Akehurst, D Bernett, C Berry, S Bird, M Buxton, K Claxton, et al.
Guidance on the use of nicotine replacement therapy and bupropion for smoking cessation. National Institute for Clinical Excellence.
[4]
R West, A McNeill, M Raw.
Smoking cessation guidelines for health professionals: an update.
Thorax, 55 (2000), pp. 987-999
[5]
A Pérez Trullén, L Clemente Jiménez.
Presente y futuro de los tratamientos para dejar de fumar.
Arch Bronconeumol, 37 (2001), pp. 241-246
[6]
CA Jiménez Ruiz, M Barrueco Ferrero, S Solano Reina, M Torrecilla García, F Domínguez Granda, JL Díaz-Maroto Muñoz, et al.
Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso.
Arch Bronconeumol, 39 (2003), pp. 35-41
[7]
CA Jiménez Ruiz, S Solano Reina, JM González de Vega, M Ruiz Pardo, S Flórez Martín, A Ramos Pinedo, et al.
Normativa para el tratamiento del tabaquismo.
Arch Bronconeumol, 335 (1999), pp. 499-506
[8]
CA Jiménez Ruiz, JI Granda Orive, S Solano Reina, F Carrión Valero, J Romero Palacios, M Barrueco Ferrero.
Recomendaciones para el tratamiento del tabaquismo.
Arch Bronconeumol, 39 (2003), pp. 409-418
[9]
J Cornuz, C Pinget, A Gilbert, F Paccaud.
Cost-effectiveness analysis of the first-line therapies for nicotine dependence.
Eur J Clin Pharmacol, 59 (2003), pp. 201-206
[10]
JI de Granda Orive, T Gutiérrez Jiménez, JM Martínez Albiach.
La financiación de los tratamientos para dejar de fumar a través del sistema nacional de salud puede incrementar su éxito.
Arch Bronconeumol, 42 (2006), pp. 666
[11]
KO Fagerström, D Balfour.
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
Expert Opin Investig Drugs, 15 (2006), pp. 107-116
[12]
C Cadoni, G di Chiara.
Differential changes in the accumbens medial shell and core dopamine in behavioural sensitization to nicotine.
Eur J Pharmacol, 387 (2000), pp. R23-R25
[13]
AR Caggiula, EC Donny, N Chaudrin, KA Perkins, FF Evans Martin, AF Sved.
Importance of nonpharmacological factors in nicotine self-administration.
Physiol Behav, 77 (2002), pp. 683-687
[14]
JE Rose, FM Behn, EC Westmen, M Johnson.
Dissociating nicotine and nonnicotine components of cigarette smoking.
Pharmacol Biochem Behav, 67 (2000), pp. 71-81
[15]
C Silagy, T Lancaster, L Stead, D Mant, G Fowler.
Nicotine replacement therapy for smoking cessation.
Cochrane Database Syst Rev, (2004),
[16]
KO Fagerström, CA Jiménez Ruiz.
Tratamiento farmacológico del tabaquismo.
Monografías Neumomadrid. Tabaquismo, pp. 101-110
[17]
S Shiffman, WG Shadel, R Niaura, MA Khayrallah, DE Jorenby, CF Ryan, et al.
Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving.
Psychopharmacology, 166 (2003), pp. 343-350
[18]
Dautzenberg M. Multicentre controlled study with nicotine pills. Proceedings of the 3rd SRNT European Conference; 2001; Paris.
[19]
S Shiffman, R Fant, R Buchhalter, J Girchell, J Henningfield.
Nicotine delivery systems.
Expert Opin Drug Deliv, 2 (2005), pp. 563-577
[20]
JE Rose, FM Behm, EC Westman, P Kukovich.
Precessation treatment with nicotine skin patch facilitates smoking cessation.
Nicotine Tob Res, 8 (2006), pp. 89-101
[21]
P Tonnessen, P Paoletti, G Gustavsson, MA Russell, R Saracci, A Gulsvik, et al.
Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial.
Eur Respir, 13 (1999), pp. 238-246
[22]
R Niaura, MA Sayette, S Shiffman.
Comparative efficacy of rapid-release nicotine gum vs. Nicorette in relieving smoking cue-provoked craving. Proceedings of the Annual Meeting of the Society for Research on Nicotine and Tobacco; 2003, February 19-22; New Orleans, Society for Research on Nicotine and Tobacco, (2003),
[23]
M Kornitzer, M Boutsen, M Dramaix, JK Thijs, G Gusstavsson.
Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial.
Prev Med, 24 (1995), pp. 41-47
[24]
CA Jiménez Ruiz, KO Fagerström.
Reducción hasta dejarlo: árbol de decisión.
Prev Tab, 8 (2006), pp. 34-37
[25]
C Pisinger, J Vestbo, K Borch-Johnsen, T Jorgensen.
Smoking reduction intervention in a large population-based study.
Prev Med, 40 (2005), pp. 1128
[26]
CT Bolliger, J-P Zellweger, T Danielsson, X van Biljon, A Robidou, A Westin, et al.
Smoking reduction with oral nicotine inhalers: double blind, randomized clinical trial of efficacy and safety.
BMJ, 321 (2000), pp. 329-333
[27]
SI Rennard, E Glover, S Leischow, DM Daughto, PM Glover, M Muramoto, et al.
Efficacy of nicotine inhaler in smoking reduction: a double-blind, randomized trial.
Nicotine Tob Res, 8 (2006), pp. 555-564
[28]
CA Jiménez Ruiz, KO Fagerström.
Un nuevo planteamiento del tratamiento del tabaquismo.
Prev Tab, 8 (2006), pp. 1
[29]
C Lerman, PG Shields, EP Wileyto, J Audrain, LH Hawk, A Pinto, et al.
Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.
Health Psychol, 22 (2003), pp. 541-548
[30]
D Balfour.
The neurobiology of tobacco dependence: a pre-clinical prespective on the role of dopamine projections to the nucleus accumbens.
Nicotine Tob Res, 6 (2004), pp. 899-912
[31]
M Jarvis, S Powell, H Marsh.
A meta-analysis of clinical studies confirms the effectiveness of bupropion SR in smoking cessation. Proceedings of the 7th Annual Conference of the Society for Research on Nicotine and Tobacco; 2001, March 23-25; Seattle, Society for Research on Nicotine and Tobacco, (2001),
[32]
JR Hughes, LF Stead, T Lancaster.
Antidepressants for smoking cessation.
Cochrane Database Sys Rev, (2004),
[33]
SL Zierler-Brown, JA Kyle.
Oral varenicline for smoking cessation.
Ann Pharmacother, 41 (2007), pp. 95-99
[34]
K Cahill, LF Stead, T Lancaster.
Nicotine receptor partial agonist for smoking cessation.
Cochrane Database Sys Rev, (2007),
[35]
J Kaper, EJ Wagena, JL Severens, CP van Schayck.
Healthcare financing systems for increasing the use of tobacco dependence treatment.
Cochrane Database Sys Rev, (2005),
Copyright © 2008. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
